MajesTEC-3: Redefining what’s possible in multiple myeloma
By Samer Al Hadidi, Mahmoud Gaballa. Despite these remarkable efficacy results, the safety profile warrants careful consideration. Grade 3 or 4 infections occurred in 54% of patients receiving teclistamab plus daratumumab, with 13 infection-related deaths.
Authors
- Samer Al Hadidi
- Mahmoud Gaballa
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Clinical Hematology International
- Published
- 2026-03-12
- DOI
- https://doi.org/10.46989/001c.158751
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Sanofi
- Legend Biotech